To confirm that rebastinib targeted CDK16 in the neuroblastoma cells, we treated SH-SY5Y cells with rebastinib in a concentration based on the determined IC50 value (Figure S5B) and performed a cellular thermal shift assay (Jafari et al., 2014). The gene discussed is CDK16; the disease is neuroblastoma.